Clinical trial

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell…

NCT00014573 · Barbara Ann Karmanos Cancer Institute, Other · Completed

Key facts

NCT number NCT00014573
Title Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Official title Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors
Lead sponsor Barbara Ann Karmanos Cancer Institute, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Brain and Central Nervous System Tumors
Intervention type Biological, Drug, Procedure
Interventions aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation and 2 more
Start date Aug 1, 1998
Primary completion Oct 1, 2004
Completion Oct 1, 2004
First posted Apr 5, 2004
Last update posted Apr 8, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies